Skip to main content
. 2017 Sep 12;10:4493–4506. doi: 10.2147/OTT.S142557

Table 1.

Correlation between OS and clinical features of PDAC patients

Variables Patients
(n=112)
MST
(days)
HR (95% CI) Log-rank P-value
Age (years)
≤60 38 593 1 0.066
>60 74 485 1.636 (0.962–2.780)
Gender
Female 53 511 1 0.523
Male 59 592 0.855 (0.529–1.382)
Alcohol historya
No 43 592 1 0.349
Yes 61 511 1.276 (0.765–2.128)
Pathologic stage
Stage I 8 236 1 0.943
Stage II 104 518 1.038 (0.375–2.872)
Pathologic T
T1/T2 14 498 1 0.466
T3 98 518 1.340 (0.608–2.949)
Pathologic N
N0 21 634 1 0.091
N1 91 511 1.818 (0.899–3.678)
Histologic grade
G1 15 518 1 0.034
G2 65 603 1.220 (0.540–2.755)
G3/G4 32 470 2.267 (0.962–5.341)
Radical resectionb
No 44 603 1 0.009
Yes 66 381 0.514 (0.310–0.852)
Radiation therapyc
No 70 473 1 0.029
Yes 30 691 0.527 (0.293–0.947)
Targeted molecular therapyd
No 29 224 1 <0.001
Yes 73 634 0.168 (0.095–0.296)

Notes:

a

Alcohol history information unavailable for 8 patients.

b

Radical resection information unavailable for 2 patients.

c

Radiation therapy information unavailable for 12 patients.

d

Targeted molecular therapy information unavailable for 10 patients.

Abbreviations: OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; MST, median survival time; HR, hazard ratio; CI, confidence interval.